ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,389,872 | +8.3% | 409,973 | +3.2% | 0.01% | +14.3% |
| Q2 2023 | $35,440,372 | -87.4% | 397,091 | -84.9% | 0.01% | -88.3% |
| Q1 2023 | $281,468,047 | -8.8% | 2,625,145 | +3.9% | 0.06% | -13.0% |
| Q4 2022 | $308,514,059 | +1.9% | 2,526,112 | -13.9% | 0.07% | -1.4% |
| Q3 2022 | $302,905,000 | -1.7% | 2,933,430 | -11.5% | 0.07% | 0.0% |
| Q2 2022 | $308,275,000 | +49.7% | 3,316,215 | +89.0% | 0.07% | +62.8% |
| Q1 2022 | $205,903,000 | +2625.4% | 1,754,458 | +3024.3% | 0.04% | +2050.0% |
| Q4 2021 | $7,555,000 | +53.1% | 56,156 | +81.3% | 0.00% | +100.0% |
| Q3 2021 | $4,936,000 | -75.7% | 30,968 | -79.9% | 0.00% | -80.0% |
| Q2 2021 | $20,281,000 | +116.1% | 154,171 | +111.7% | 0.01% | +150.0% |
| Q1 2021 | $9,387,000 | -18.6% | 72,833 | +5.4% | 0.00% | -33.3% |
| Q4 2020 | $11,527,000 | -11.8% | 69,115 | -18.4% | 0.00% | -25.0% |
| Q3 2020 | $13,066,000 | +71.1% | 84,672 | +64.0% | 0.00% | +100.0% |
| Q2 2020 | $7,637,000 | +52.6% | 51,633 | +16.2% | 0.00% | 0.0% |
| Q1 2020 | $5,005,000 | +93.2% | 44,442 | +138.6% | 0.00% | +100.0% |
| Q4 2019 | $2,591,000 | -35.8% | 18,623 | -55.5% | 0.00% | 0.0% |
| Q3 2019 | $4,033,000 | +100.0% | 41,874 | +139.0% | 0.00% | 0.0% |
| Q2 2019 | $2,017,000 | -19.0% | 17,517 | -17.2% | 0.00% | 0.0% |
| Q1 2019 | $2,491,000 | +16.6% | 21,166 | -37.9% | 0.00% | 0.0% |
| Q4 2018 | $2,137,000 | +94.1% | 34,100 | +119.5% | 0.00% | – |
| Q3 2018 | $1,101,000 | -36.6% | 15,535 | -40.5% | 0.00% | – |
| Q2 2018 | $1,736,000 | +4.3% | 26,102 | +2.5% | 0.00% | – |
| Q1 2018 | $1,665,000 | +156.2% | 25,454 | +56.8% | 0.00% | – |
| Q4 2017 | $650,000 | – | 16,233 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |